Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terry Rollins

Dermatology Voorhees, NJ Medical Doctor

NPI 1235119116 CMS profile 55051

707 White Horse Rd, Suite C103, Voorhees, NJ 08043

Open in the dashboard

General payments

$5,291

346 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terry Rollins of Voorhees, NJ is reported in the CMS Open Payments database as having received $5,291 across 346 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $600 35
2024 General $910 43
2023 General $701 43
2022 General $822 60
2021 General $953 67
2020 General $382 29
2019 General $922 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terry Rollins
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Terry Rollins were reported at $600. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Terry Rollins Dermatology median Middle half National median
2019 $922 $454 $129–$1,240 $163
2020 $382 $235 $81–$756 $114
2021 $953 $377 $108–$1,108 $132
2022 $822 $514 $143–$1,391 $149
2023 $701 $607 $159–$1,674 $160
2024 $910 $751 $204–$1,903 $164
2025 $600 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $833 62 payments
  2. Janssen Biotech, Inc. $818 32 payments
  3. Novartis Pharmaceuticals Corporation $494 38 payments
  4. UCB, Inc. $451 34 payments
  5. Sun Pharmaceutical Industries Inc. $447 26 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $394 25 payments
  7. Regeneron Healthcare Solutions, Inc. $258 18 payments
  8. Lilly USA, LLC $248 17 payments
  9. LEO Pharma Inc. $197 14 payments
  10. Pfizer Inc. $183 13 payments
  11. Other $967 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,654 338 payments
  2. Education $637 8 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $695 19 payments
  2. SKYRIZI $577 43 payments
  3. Cimzia $350 26 payments
  4. ILUMYA $291 21 payments
  5. DUOBRII $287 17 payments
  6. HUMIRA $279 21 payments
  7. DUPIXENT $225 16 payments
  8. TALTZ $202 14 payments
  9. COSENTYX $187 17 payments
  10. EUCRISA $165 12 payments
  11. Other $3,056 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,446

Median for Dermatology: 534

Drug cost

$1,020,212

Median for Dermatology: $67,151

Branded share of claims

11.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bimzelx Autoinjector Bimekizumab-Bkzx Brand 19 $273,781
Skyrizi Pen Risankizumab-Rzaa Brand 13 $268,727
Otezla Apremilast Brand 28 $134,348
Cimzia (2 Pack) Certolizumab Pegol Brand 12 $133,425
Rinvoq Upadacitinib Brand 19 $120,475
Dupixent Syringe Dupilumab Brand 15 $55,274
Betamethasone Dipropionate Generic 166 $7,544
Clobetasol Propionate Generic 109 $4,018
Ketoconazole Generic 207 $3,925
Doxycycline Hyclate Generic 170 $3,836

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$1,331,521

Of which drugs: $50,672

Medicare patients

1,660

Average age 76

Services billed

24,932

745 women, 915 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 34%
Diabetes 25%
Atrial fibrillation 19%
Cancer 19%
Chronic kidney disease 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 15 5,400 $6,152
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 67 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $201
$201 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $60
  • GENZYME CORPORATION $45
$105 15 —
Bimzelx
  • UCB, Inc. $72
$72 19 —
SKYRIZI
  • AbbVie, Inc. $64
$64 13 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

346 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record